Astellas isavuconazole gains FDA 'infectious disease' status
This article was originally published in Scrip
Executive Summary
The US FDA has designated Astellas Pharma's isavuconazole a qualified infectious disease product (QIDP) – a status that could garner the experimental medicine an additional five years of market exclusivity if approved.